News Focus
News Focus
icon url

jonnyrocket

02/17/12 11:30 AM

#75468 RE: geocappy1 #75467

On the last couple of calls King started saying "out-source" the Hepc indication along with "out-license"...that told me that they weren't expecting a big license, and as you say little upfront money. Made me think if they can partner it (or out-source it), the agreement would be for the company acquiring would continue all development costs, and we'd get future sales royalties if it ever got to market. Maybe some upfront money, but not much IMO - kind of like our 2 most recent deals with Affitech and Stason. I heard him say "out-source" (i think that was the term he used) twice after he had been saying licensing only for a while. I already mentioned this a couple months ago when I heard it again on the Dec call.
icon url

freethemice

02/17/12 11:44 AM

#75470 RE: geocappy1 #75467

Geo,
I think you are on the right track here. I believe that bavi does have a roll in HCV treatment. However,
as you say, it will require more resources to figure out exactly how it will work. It might take a real
commitment of time and money to do some small trials testing various combinations of dosage
and timing to get some real answers. I just think Peregrine doesn't want to make that commitment right now.